Skip to main content

Through eight lenses

01

Science

Alpha-2 agonists (xylazine, medetomidine — veterinary sedatives), nitazenes as μ-opioid agonists (synthesized in 1950s, never approved, re-emerging), kratom mitragynine partial μ-agonist + alpha-2, tianeptine atypical antidepressant with opioid activity at high doses.

02

Biology

Xylazine causes necrotic skin ulcers characteristic + prolonged sedation not reversed by naloxone; nitazenes act like high-potency fentanyl analogs (naloxone-reversible, higher dosing may be needed); kratom has its own withdrawal syndrome; tianeptine "gas station heroin" causing emergency-dept surges.

03

Psychology

Dependence patterns mirror the parent class but often with gaps in clinical recognition.

04

Policy

DEA scheduling scramble — xylazine FDA-declared emerging threat, nitazene analogs being scheduled piecemeal, kratom DEA deferred twice, tianeptine state-by-state patchwork.

06

Social & Cultural

The "legal high" marketing arms race; the gap between policy and supply.

07

Treatment

Xylazine wound care + opioid co-treatment; nitazene overdose reversal with naloxone; kratom dependence — buprenorphine effective; tianeptine dependence — like opioids.

08

Harm Reduction

Test strips for xylazine + nitazenes (where available), stay with person during prolonged sedation, don't use alone, high-dose naloxone availability.

Other substances in Novel & Emerging Psychoactives